drugset
drugset / Trial / NCT03637387

802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia

NCT03637387 ↗

Phase 3 Withdrawn Biogen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to evaluate the efficacy of BIIB074 in treating pain experienced by participants with trigeminal neuralgia (TN). The secondary objectives are to investigate the safety and tolerability of BIIB074 in participants with TN and to evaluate the population pharmacokinetic(s) (PK) of BIIB074.

Timeline

Start
2023-03-01
Primary completion
2025-08-18
Completion
2026-09-29

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject Vixotrigine Small molecule — Oral

Indications

trigeminal neuralgia